Analyzing the efficacy studies of the three Anti-IL5 mAbs, it is important to focus on the primary outcome, which is, for mepolizumab and benralizumab [19, 21], the reduction in annual asthma exacerbation numbers and, limited to reslizumab, the improvement in lung function test [24]. The gene discussed is IL5; the disease is asthma.